ABSTRACT
Interferometric gravitational wave detectors operate with high optical power in their arms in order to achieve high shot-noise limited strain sensitivity. A significant limitation to increasing the optical power is the phenomenon of three-mode parametric instabilities, in which the laser field in the arm cavities is scattered into higher-order optical modes by acoustic modes of the cavity mirrors. The optical modes can further drive the acoustic modes via radiation pressure, potentially producing an exponential buildup. One proposed technique to stabilize parametric instability is active damping of acoustic modes. We report here the first demonstration of damping a parametrically unstable mode using active feedback forces on the cavity mirror. A 15 538 Hz mode that grew exponentially with a time constant of 182 sec was damped using electrostatic actuation, with a resulting decay time constant of 23 sec. An average control force of 0.03 nN was required to maintain the acoustic mode at its minimum amplitude.
ABSTRACT
This paper presents an analysis of the transient behavior of the Advanced LIGO (Laser Interferometer Gravitational-wave Observatory) suspensions used to seismically isolate the optics. We have characterized the transients in the longitudinal motion of the quadruple suspensions during Advanced LIGO's first observing run. Propagation of transients between stages is consistent with modeled transfer functions, such that transient motion originating at the top of the suspension chain is significantly reduced in amplitude at the test mass. We find that there are transients seen by the longitudinal motion monitors of quadruple suspensions, but they are not significantly correlated with transient motion above the noise floor in the gravitational wave strain data, and therefore do not present a dominant source of background noise in the searches for transient gravitational wave signals. Using the suspension transfer functions, we compared the transients in a week of gravitational wave strain data with transients from a quadruple suspension. Of the strain transients between 10 and 60 Hz, 84% are loud enough that they would have appeared above the sensor noise in the top stage quadruple suspension monitors if they had originated at that stage at the same frequencies. We find no significant temporal correlation with the suspension transients in that stage, so we can rule out suspension motion originating at the top stage as the cause of those transients. However, only 3.2% of the gravitational wave strain transients are loud enough that they would have been seen by the second stage suspension sensors, and none of them are above the sensor noise levels of the penultimate stage. Therefore, we cannot eliminate the possibility of transient noise in the detectors originating in the intermediate stages of the suspension below the sensing noise.
ABSTRACT
BACKGROUND AND PURPOSE: The histamine H4 receptor is widely expressed in cells of immune origin and has been shown to play a role in a variety of inflammatory processes mediated by histamine. In this report, we describe the in vitro and in vivo anti-inflammatory properties of a potent histamine H4 receptor antagonist, A-940894 (4-piperazin-1-yl-6,7-dihydro-5H-benzo[6,7]cyclohepta[1,2-d]pyrimidin-2-ylamine). EXPERIMENTAL APPROACH: We have analysed the pharmacological profile of A-940894 at mouse native, rat recombinant and human recombinant and native, histamine H4 receptors by radioligand binding, calcium mobilization, mast cell shape change, eosinophil chemotaxis assays and in the mouse model of zymosan-induced peritonitis. KEY RESULTS: A-940894 potently binds to both human and rat histamine H4 receptors and exhibits considerably lower affinity for the human histamine H1, H2 or H3 receptors. It potently blocked histamine-evoked calcium mobilization in the fluorometric imaging plate reader assays and inhibited histamine-induced shape change of mouse bone marrow-derived mast cells and chemotaxis of human eosinophils in vitro. In a mouse mast cell-dependent model of zymosan-induced peritonitis, A-940894 significantly blocked neutrophil influx and reduced intraperitoneal prostaglandin D2 levels. Finally, A-940894 has good pharmacokinetic properties, including half-life and oral bioavailability in rats and mice. CONCLUSIONS AND IMPLICATIONS: These data suggest that A-940894 is a potent and selective histamine H4 receptor antagonist with pharmacokinetic properties suitable for long-term in vivo testing and could serve as a useful tool for the further characterization of histamine H4 receptor pharmacology.
Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/pharmacology , Piperazines/pharmacology , Pyrimidines/pharmacology , Receptors, G-Protein-Coupled/antagonists & inhibitors , Animals , Anti-Inflammatory Agents, Non-Steroidal/pharmacokinetics , Binding, Competitive , Calcium/metabolism , Cell Shape , Chemotaxis , Eosinophils/drug effects , Eosinophils/physiology , Female , Histamine/pharmacology , Humans , Male , Mast Cells/cytology , Mast Cells/drug effects , Mice , Mice, Inbred BALB C , Peritonitis/chemically induced , Peritonitis/drug therapy , Peritonitis/immunology , Piperazines/pharmacokinetics , Prostaglandin D2/metabolism , Pyrimidines/pharmacokinetics , RNA, Messenger/biosynthesis , Radioligand Assay , Rats , Rats, Sprague-Dawley , Receptors, G-Protein-Coupled/biosynthesis , Receptors, G-Protein-Coupled/genetics , Receptors, Histamine/biosynthesis , Receptors, Histamine/genetics , Receptors, Histamine H4 , Recombinant Proteins/antagonists & inhibitors , ZymosanABSTRACT
BACKGROUND AND PURPOSE: The histamine H3 receptor antagonist radioligand [3H]-A-349821 was characterized as a radiotracer for assessing in vivo receptor occupancy by H3 receptor antagonists that affect behaviour. This model was established as an alternative to ex vivo binding methods, for relating antagonist H3 receptor occupancy to blood levels and efficacy in preclinical models. EXPERIMENTAL APPROACH: In vivo cerebral cortical H3 receptor occupancy by [3H]-A-349821 was determined in rats from differences in [3H]-A-349821 levels in the isolated cortex and cerebellum, a brain region with low levels of H3 receptors. Comparisons were made to relate antagonist H3 receptor occupancy to blood levels and efficacy in a preclinical model of cognition, the five-trial inhibitory avoidance response in rat pups. KEY RESULTS: In adult rats, [3H]-A-349821, 1.5 microg x kg(-1), penetrated into the brain and cleared more rapidly from cerebellum than cortex; optimally, [3H]-A-349821 levels were twofold higher in the latter. With increasing [3H]-A-349821 doses, cortical H3 receptor occupancy was saturable with a binding capacity consistent with in vitro binding in cortex membranes. In studies using tracer [3H]-A-349821 doses, ABT-239 and other H3 receptor antagonists inhibited H3 receptor occupancy by [3H]-A-349821 in a dose-dependent manner. Blood levels of the antagonists corresponding to H3 receptor occupancy were consistent with blood levels associated with efficacy in the five-trial inhibitory avoidance response. CONCLUSIONS AND IMPLICATIONS: When employed as an occupancy radiotracer, [3H]-A-349821 provided valid measurements of in vivo H3 receptor occupancy, which may be helpful in guiding and interpreting clinical studies of H3 receptor antagonists.
Subject(s)
Biphenyl Compounds/pharmacology , Brain/metabolism , Cognition/drug effects , Histamine H3 Antagonists/pharmacology , Receptors, Histamine H3/metabolism , Animals , Autoradiography , Avoidance Learning/drug effects , Binding, Competitive , Biphenyl Compounds/pharmacokinetics , Cell Membrane/drug effects , Cell Membrane/metabolism , Cerebellum/metabolism , Cerebral Cortex/metabolism , Histamine H3 Antagonists/pharmacokinetics , In Vitro Techniques , Male , Radioligand Assay , Rats , Rats, Sprague-Dawley , Tissue Distribution , TritiumABSTRACT
The histamine H3 receptor, first described in 1983 as a histamine autoreceptor and later shown to also function as a heteroreceptor that regulates the release of other neurotransmitters, has been the focus of research by numerous laboratories as it represents an attractive drug target for a number of indications including cognition. The purpose of this review is to acquaint the reader with the current understanding of H3 receptor localization and function as a modulator of neurotransmitter release and its effects on cognitive processes, as well as to provide an update on selected H3 antagonists in various states of preclinical and clinical advancement. Blockade of centrally localized H3 receptors by selective H3 receptor antagonists has been shown to enhance the release of neurotransmitters such as histamine, ACh, dopamine and norepinephrine, among others, which play important roles in cognitive processes. The cognitive-enhancing effects of H3 antagonists across multiple cognitive domains in a wide number of preclinical cognition models also bolster confidence in this therapeutic approach for the treatment of attention deficit hyperactivity disorder, Alzheimer's disease and schizophrenia. However, although a number of clinical studies examining the efficacy of H3 receptor antagonists for a variety of cognitive disorders are currently underway, no clinical proof of concept for an H3 receptor antagonist has been reported to date. The discovery of effective H3 antagonists as therapeutic agents for the novel treatment of cognitive disorders will only be accomplished through continued research efforts that further our insights into the functions of the H3 receptor.
Subject(s)
Cognition Disorders/drug therapy , Receptors, Histamine H3/drug effects , Receptors, Histamine H3/physiology , Animals , Cognition/physiology , Histamine/physiology , Histamine H3 Antagonists/pharmacology , Histamine H3 Antagonists/therapeutic use , Humans , Memory/drug effects , Neurotransmitter Agents/metabolism , Signal Transduction/drug effects , Signal Transduction/physiologySubject(s)
Histamine H3 Antagonists , Trans-Activators/metabolism , Animals , Behavior, Animal , Benzofurans/chemistry , Cyclobutanes/chemistry , Histamine H3 Antagonists/chemistry , Histamine H3 Antagonists/metabolism , Humans , Male , Molecular Structure , Naphthalenes/chemistry , Radioligand Assay , Rats , Receptors, Histamine H3/metabolism , Trans-Activators/genetics , Transcriptional Regulator ERGSubject(s)
Alkaloids , Histamine Antagonists , Receptors, Histamine H3/metabolism , Alkaloids/chemistry , Alkaloids/metabolism , Animals , Dose-Response Relationship, Drug , Drug Design , Guanosine Triphosphate/metabolism , Histamine Agonists/metabolism , Histamine Antagonists/chemistry , Histamine Antagonists/metabolism , Humans , Male , Molecular Structure , Rats , Structure-Activity RelationshipABSTRACT
To examine trends in HIV prevalence in the US household population, serum or urine samples from 2 National Health and Nutrition Examinations Surveys (NHANES) (1988-1994 and 1999-2002), were tested for HIV antibody. In the 1999 to 2002 survey, data on risk behaviors, CD4 T lymphocytes, and antiretroviral therapy (ART) were also available. In the 1988 to 1994 survey, there were 59 positive individuals of 11,203 tested. In NHANES 1999 to 2002, there were 32 positive individuals of 5926 tested. The prevalence of HIV infection among those aged 18 to 39 years in NHANES 1988 to 1994 was 0.38% (95% confidence interval [CI]: 0.22-0.68) as compared with 0.37% (95% CI: 0.17 to 0.80) in 1999 to 2002. Prevalence did not change significantly between surveys in any race and/or ethnic or gender group among 18- to 39-year-old participants. HIV prevalence was 3.58% (95% CI: 1.88 to 6.71) among non-Hispanic blacks in the 40- to 49-year-old age group in 1999 to 2002, but the age range available in NHANES 1988 to 1994 was 18 to 59 years and does not allow direct comparison of prevalence. Cocaine use and the presence of herpes simplex virus-2 antibody were the only significant risk factors for HIV infection for non-Hispanic blacks. Fifty-eight percent of infected individuals not reporting ART had CD4 T-lymphocyte counts < 200 cells/mm3 compared with 18.2% on therapy and 12.5% of participants newly informed of their HIV status.
Subject(s)
Family Characteristics , HIV Infections/epidemiology , Age Distribution , Ethnicity , Female , HIV Infections/transmission , Health Surveys , Humans , Male , Poverty , Risk-Taking , Sexual Behavior , Socioeconomic Factors , United States/epidemiology , United States Food and Drug AdministrationSubject(s)
Benzofurans/pharmacology , Cognition/drug effects , Histamine Antagonists/pharmacology , Pyrrolidines/pharmacology , Receptors, Histamine H3/metabolism , Schizophrenia/drug therapy , Schizophrenia/metabolism , Animals , Benzofurans/therapeutic use , Cognition/physiology , Histamine Antagonists/therapeutic use , Memory/drug effects , Memory/physiology , Mice , Mice, Inbred DBA , Models, Animal , Pyrrolidines/therapeutic use , Rats , Rats, WistarSubject(s)
Biphenyl Compounds/pharmacology , Histamine Antagonists/pharmacology , Nitriles/pharmacology , Obesity/metabolism , Obesity/prevention & control , Pyrrolidines/pharmacology , Receptors, Histamine H3/metabolism , Animals , Biphenyl Compounds/adverse effects , Biphenyl Compounds/chemistry , Diet , Dietary Fats/administration & dosage , Dietary Fats/pharmacology , Histamine Agonists/chemistry , Histamine Agonists/pharmacology , Histamine Antagonists/adverse effects , Histamine Antagonists/chemistry , Male , Mice , Mice, Inbred C57BL , Molecular Structure , Nitriles/adverse effects , Nitriles/chemistry , Obesity/chemically induced , Pyrrolidines/adverse effects , Pyrrolidines/chemistryABSTRACT
Adenosine (ADO) is an endogenous homeostatic inhibitory neuromodulator that reduces cellular excitability at sites of tissue injury and inflammation. Inhibition of adenosine kinase (AK), the primary metabolic enzyme for ADO, selectively increases ADO concentrations at sites of tissue trauma and enhances the analgesic and antiinflammatory actions of ADO. Optimization of the high-throughput screening lead, 4-amino-7-aryl-substituted pteridine (5) (AK IC(50) = 440 nM), led to the identification of compound 21 (4-amino-5-(3-bromophenyl)-7-(6-morpholino-pyridin-3-yl)pyrido [2,3-d]pyrimidine, ABT-702), a novel, potent (AK IC(50) = 1.7 nM) non-nucleoside AK inhibitor with oral activity in animal models of pain and inflammation.
Subject(s)
Adenosine Kinase/antagonists & inhibitors , Anti-Inflammatory Agents, Non-Steroidal/chemical synthesis , Enzyme Inhibitors/chemical synthesis , Enzyme Inhibitors/pharmacology , Morpholines/chemical synthesis , Morpholines/pharmacology , Pyrimidines/chemical synthesis , Pyrimidines/pharmacology , Animals , Anti-Inflammatory Agents, Non-Steroidal/pharmacology , Drug Design , Formaldehyde , Humans , Models, Molecular , Molecular Conformation , Pain Measurement , Rats , Tumor Cells, CulturedABSTRACT
Extracellular levels of adenosine (ADO) can be raised through inhibition of adenosine kinase (AK), a primary metabolic enzyme for ADO. AK inhibitors have shown antinociceptive activity in a variety of animal models of nociception. The present study investigated the antinociceptive actions of a novel and selective AK inhibitor, A-134974 (IC(50)=60 pM), in a rat model of neuropathic pain (ligations of the L5/L6 spinal nerves) and explored the relative contributions of supraspinal, spinal and peripheral sites to the actions of A-134974. Systemic A-134974 dose-dependently reduced tactile allodynia (ED(50)=5 micromol/kg, i.p.) for up to 2 h. Fall latencies in the rotorod test of motor coordination were unaffected by systemic administration of A-134974 (at doses up to 30 micromol/kg, i.p.). Administration of A-134974 intrathecally (i.t.) was more potent (ED(50)=10 nmol) in relieving tactile allodynia than delivering the compound by intracerebroventricular (ED(50)>100 nmol, i.c.v.) or intraplantar (ED(50)>500 nmol) routes suggesting that spinal sites of action are the primary contributors to the anti-allodynic action of A-134974. The anti-allodynic effects of systemic A-134974 (10 micromol/kg, i.p.) were antagonized by the non-selective ADO receptor antagonist, theophylline (30-500 nmol) administered i.t. These data demonstrate that the novel AK inhibitor A-134974 potently reduces tactile allodynia through interactions with spinal sites and adds to the growing evidence that AK inhibitors may be useful as analgesic agents in a broad spectrum of pain states.
Subject(s)
Enzyme Inhibitors/pharmacology , Hyperalgesia/drug therapy , Nociceptors/drug effects , Nucleosides/pharmacology , Pain/drug therapy , Peripheral Nervous System Diseases/drug therapy , Posterior Horn Cells/drug effects , Adenosine Kinase/antagonists & inhibitors , Adenosine Kinase/metabolism , Animals , Disease Models, Animal , Dose-Response Relationship, Drug , Hyperalgesia/metabolism , Hyperalgesia/physiopathology , Male , Nerve Crush/adverse effects , Nociceptors/metabolism , Nociceptors/physiopathology , Pain/metabolism , Pain/physiopathology , Pain Measurement/drug effects , Peripheral Nervous System Diseases/metabolism , Peripheral Nervous System Diseases/physiopathology , Phosphodiesterase Inhibitors/pharmacology , Physical Stimulation/adverse effects , Posterior Horn Cells/metabolism , Rats , Rats, Sprague-Dawley , Theophylline/pharmacologyABSTRACT
The present study investigated 1) antihyperalgesic actions of a novel and selective adenosine kinase (AK) inhibitor, A-134974 (IC(50) = 60 pM), in the carrageenan model of thermal hyperalgesia; 2) effects of A-134974 on locomotor activity; and 3) relative contributions of supraspinal, spinal, and peripheral sites to the actions of A-134974. Systemic A-134974 (i.p.) dose dependently reduced hyperalgesia (ED(50) = 1 micromol/kg) and at higher doses, reduced locomotor activity (ED(50) = 16 micromol/kg). Administration of A-134974 intrathecally (i.t.) was more potent (ED(50) = 6 nmol) at producing antihyperalgesia than delivering the compound by intracerebralventricular (ED(50) = 100 nmol, i.c.v.) or intraplantar (ED(50) >300 nmol) routes. In contrast, i.c.v. administration of A-134974 was more effective in reducing locomotor activity than i.t. administration (ED(50) values were 1 and >100 nmol, respectively). Increasing the pretreatment time for i.t.-delivered A-134974 caused a greater reduction in locomotor activity (ED(50) = 10 nmol). This was due to diffusion of A-134974 (i.t.) to supraspinal sites. The antihyperalgesic effects of systemic A-134974 were antagonized by the adenosine receptor antagonist theophylline (THEO, 30-500 nmol) administered i.t., but not i.c.v. In the locomotor assay, i.t.-injected THEO did not antagonize hypomobility caused by systemic or i.t. administration of A-134974. However, i.c.v. infusion of THEO did block the hypomotive actions of i.c.v.-, i.t.-, and i.p.-administered A-134974. These data demonstrate that the novel AK inhibitor A-134974 potently reduces thermal hyperalgesia primarily through interactions with spinal sites, whereas its ability to depress locomotor activity is predominantly mediated by supraspinal sites.
Subject(s)
Adenosine Kinase/antagonists & inhibitors , Anti-Inflammatory Agents, Non-Steroidal/pharmacology , Enzyme Inhibitors/pharmacology , Hyperalgesia/prevention & control , Inflammation/prevention & control , Motor Activity/drug effects , Nucleosides/pharmacology , Animals , Anti-Inflammatory Agents, Non-Steroidal/administration & dosage , Carrageenan , Central Nervous System/drug effects , Enzyme Inhibitors/administration & dosage , Hyperalgesia/chemically induced , Inflammation/chemically induced , Injections, Intraventricular , Injections, Spinal , Male , Peripheral Nervous System/drug effects , Rats , Rats, Sprague-Dawley , Spinal Cord/drug effectsABSTRACT
The synthesis and SAR of a novel series of non-nucleoside pyridopyrimidine inhibitors of the enzyme adenosine kinase (AK) are described. It was found that pyridopyrimidines with a broad range of medium and large non-polar substituents at the 5-position potently inhibited AK activity. A narrower range of analogues was capable of potently inhibiting adenosine phosphorylation in intact cells indicating an enhanced ability of these analogues to penetrate cell membranes. Potent AK inhibitors were found to effectively reduce nociception in animal models of thermal hyperalgesia and persistent pain.